

Cryotherapy - a new vision of precision

Galil Medical delivers a new era of cryotherapy for minimally invasive, targeted ablation of benign and cancerous tumours, with rapid recovery and enhanced quality of life for patients.

A strong commitment to technological innovation has enabled Galil Medical to develop the smallest diameter cryoablation needles available in the market. These patented 17-gauge needles enable sculpting of a precise freeze zone to match the size and shape of the target tumour.

Clinical data shows very positive results for prostate cryotherapy as a primary prostate cancer treatment as well as a salvage treatment, when other treatments have failed. Long-term 10-year data suggests that prostate cryotherapy is able to deliver disease-free rates comparable to radical prostatectomy and radiation, with the benefit of lower rates of incontinence, shorter recovery periods and relatively minimal complications.

Renal cryoablation can be performed with a laparoscopic or percutaneous approach. Of the available ablation technologies, cryoablation has the lowest recurrence rate and the least morbidity.

	Cryoablation	RF ablation
Number of Patients	326	277
Reported Complications	10.6%	13.9%
Follow-up period	30.8 mo	10 mo
Tumor Recurrence	4.6%	7.9%

Source: Comparison of cryoablation, radiofrequency ablation and high-intensity focused ultrasound for treating small renal tumours. Kyle J. Weld and Jaime Landman. BJU International, 2005, 96, 1224-1229.



“...results suggest that cryotherapy offers a safe and effective alternative for the primary and secondary treatment of prostate cancer.”

Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease. J. Cresswell, S. Asterling, M. Chaudhary, N. Sheikh and D. Greene. BJU International 97 (5), 969-974.

Prostate cryoablation “is safe, well-tolerated and effective for the salvage treatment of prostate cancer. It is minimally invasive ...and for patients in whom RT has failed, it offers an additional hope of cure.”

Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. M. Ismail, S. Ahmed, C. Kastner and J. Davies. BJU International 100 (4), 760-764.

“Renal cryoablation is safe and offers a minimally invasive nephron-sparing alternative. ...intermediate-term success rate with cryoablation therapy is equivalent to that of extirpative therapy.”


Laparoscopic Cryoablation for Small Renal Masses: Three-Year Follow-up. K. J. Weld, R. S. Figenshau, R. Venkatesh, S. B. Bhayani, C. D. Ames, R. V. Clayman, and J. Landman. UROLOGY 69:448-451, 2007.



A New Vision of Precision

Visit us at stand D05 at EAU

New PRESICE™ Technology for Prostate and Renal Cryotherapy



- Designed specifically for urologists
- Excellent control and clinical results
- Innovative 17-gauge cryoablation needles
- Multi-point thermal sensors (MTS™)
- IceVue™ planning and simulation software
- Variable iceball sizes
- Optimized theatre space & workflow

Minimally invasive

Targeted ablation

Primary & Salvage

Accurate

Real-time monitoring

www.galilmedical.com



LIVE CASE DEMONSTRATION - RENAL CRYOTHERAPY

08.30-13.45 Wednesday 26 March: Kidney Unlimited

Please visit stand D05 for a full programme overview of cryotherapy at EAU 08